Atypical reversible leucoencephalopathy syndrome after bevacizumab/folfox regimen for metastatic colon cancer.
We are reporting a case of multifocal reversible leucoencephalopathy syndrome induced by chemotherapy based on Folfox-Bevacizumab regimen. A 44-year-old female, with no history of hypertension, received a chemotherapy based on Folfox-Bevacizumab for her metastatic colon cancer (5 FU: 325 mg/m(2) d1 by intravenous infusion, Oxaliplatin 80 mg/m(2) d1, and Bevacizumab: 7.5 mg/Kg d1). During the fourth cure, she presented delirium, seizures, and visual disturbances. The computed tomography (CT) of the brain showed hypodense lesions of the white matter of frontal, parietal, and occipital lobes, which were bilateral and symmetrical. The clinical table was reversible under symptomatic treatment.
Department of Medical Oncology, National Institute of Oncology, Rabat 10000, Morocco ; Université Mohammed V-Souissi, Rabat 8007, Morocco.
Narimane
N
Salmi
Department of Medical Oncology, National Institute of Oncology, Rabat 10000, Morocco ; Université Mohammed V-Souissi, Rabat 8007, Morocco.
Ibrahim
I
Elghissassi
Department of Medical Oncology, National Institute of Oncology, Rabat 10000, Morocco ; Université Mohammed V-Souissi, Rabat 8007, Morocco.
Khadija
K
Bellahammou
Department of Medical Oncology, National Institute of Oncology, Rabat 10000, Morocco ; Université Mohammed V-Souissi, Rabat 8007, Morocco.
Asmaa
A
Lakhdissi
Department of Medical Oncology, National Institute of Oncology, Rabat 10000, Morocco ; Université Mohammed V-Souissi, Rabat 8007, Morocco.
Hind
H
Mrabti
Department of Medical Oncology, National Institute of Oncology, Rabat 10000, Morocco ; Université Mohammed V-Souissi, Rabat 8007, Morocco.
Hassan
H
Errihani